Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in infective endocarditis
Abstract Funding Acknowledgements Type of funding sources: None. Background 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used for the diagnosis of infective endocarditis (IE), but its prognostic value remains unknown. Objectives This study so...
Gespeichert in:
Veröffentlicht in: | European heart journal cardiovascular imaging 2021-02, Vol.22 (Supplement_1) |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is commonly used for the diagnosis of infective endocarditis (IE), but its prognostic value remains unknown.
Objectives
This study sought to assess the prognostic value of 18F-FDG PET/CT in prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE).
Methods
This study prospectively included 173 consecutive patients (109 PVE and 64 NVE) with definite left-sided IE who had an 18F-FDG PET/CT and were followed-up for 1 year. The primary endpoint was a composite of major cardiac events: death, recurrence of IE, acute cardiac failure, nonscheduled hospitalization for cardiovascular indication, and new embolic event.
Results
18F-FDG PET/CT was positive in 100 (58%) patients, 83% (n = 90 of 109) in the PVE, and 16% (n = 10 of 64) in the NVE group. At a mean follow-up of 225 days (interquartile range: 199 to 251 days), the primary endpoint occurred in 94 (54%) patients: 63 (58%) in the PVE group and 31 (48%) in the NVE group. In the PVE group, positive 18F-FDG PET/CT was significantly associated with a higher rate of primary endpoint (hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 1.1 to 6.7; p = 0.04). Moderate to intense 18F-FDG valvular uptake was also associated with worse outcome (HR: 2.3; 95% CI: 1.3 to 4.5; p = 0.03) and to new embolic events in PVE (HR: 7.5; 95% CI: 1.24 to 45.2; p = 0.03) and in NVE (HR: 8.8; 95% CI: 1.1 to 69.5; p = 0.02). In the NVE group, 18F-FDG PET/CT was not associated with occurrence of the primary endpoint CONCLUSIONS: In addition to its good diagnostic performance, 18F-FDG PET/CT is predictive of major cardiac events in PVE and new embolic events within the first year following IE.
Primary Endpoint Occurrence: Univariate and Multivariate Analysis in PVE
Univariate HR (95% CI)
p Value
Multivariate HR (95% CI)
p Value
Renal insufficiency at admission
2.16 (1.00-4.68)
0.05
CRP >100 mg/l
2.46 (1.04-5.89)
0.02
1.90 (1.10-3.40)
0.03
Staphylococcus aureus
2.70 (1.10-6.55)
0.03
Severe valvular regurgitation
2.55 (1.01-6.41)
0.05
1.20 (0.70-2.10)
0.68
Echographic complications
1.15 (0.54-2.46)
0.72
Vegetation length >10 mm
2.53 (1.19-4.60)
0.03
Positive 18F-FDG PET/CT
3.74 (1.30-10.80)
0.02
2.70 (1.10-6.70)
0.04
Moderate to intense 18FDG valvular uptake
2.70 (1.20-6.30)
0.02
2.30 (1.30-4.50)
0.03
Abstract Figure. |
---|---|
ISSN: | 2047-2404 2047-2412 |
DOI: | 10.1093/ehjci/jeaa356.348 |